Last $13.64 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 08/7/14 All times are local (Market data is delayed by at least 15 minutes).

galectin therapeutics - uts (GALTU) Snapshot

Open
$12.81
Previous Close
$13.64
Day High
$13.64
Day Low
$12.81
52 Week High
01/28/14 - $54.06
52 Week Low
07/29/14 - $11.35
Market Cap
249.8M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
18.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GALECTIN THERAPEUTICS - UTS (GALTU)

Related News

No related news articles were found.

galectin therapeutics - uts (GALTU) Related Businessweek News

No Related Businessweek News Found

galectin therapeutics - uts (GALTU) Details

Galectin Therapeutics Inc., a development stage company, is engaged in the research and development of therapies for fibrotic disease and cancer. The company’s lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trials in Europe as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer. Galectin Therapeutics Inc., through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

galectin therapeutics - uts (GALTU) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $569.7K
Executive Chairman
Total Annual Compensation: $360.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $127.3K
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $260.0K
Compensation as of Fiscal Year 2013.

galectin therapeutics - uts (GALTU) Key Developments

Galectin Therapeutics, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Galectin Therapeutics, Inc. reported consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total operating loss was $3.375 million compared with $2.547 million for the same period last year. Net loss applicable to common stock was $3.731 million or $0.17 basic and diluted per share compared with $11.641 million or $0.72 basic and diluted per share for the same period last year. Excluding non-cash charge, the increase in net loss applicable to common stock in the quarter ended June 30, 2014 over 2013 is primarily due to increases in clinical trial costs related to Phase 1 clinical trial, non-cash stock-based compensation expense and legal costs. For the six months, the company reported total operating loss was $8.219 million compared with $5.755 million for the same period last year. Net loss applicable to common stock was $9.139 million or $0.42 basic and diluted per share compared with $15.113 million or $0.94 basic and diluted per share for the same period last year.

The Rosen Law Firm Files Securities Class Action Against Galectin Therapeutics, Inc

The Rosen Law Firm, P.A. announces that a class action lawsuit has been filed on behalf of purchasers of Galectin Therapeutics, Inc. securities between January 6, 2014 and July 28, 2014, inclusive asserting violations of federal securities laws. According the lawsuit, Galectin and certain of its officers and directors made false and misleading statements concerning one of its lead product candidates -- GR-MD-02 that seeks to treat the liver disease NASH.

Galectin Therapeutics, Inc. Presents at FSXinterlinked Investment Conference, Aug-01-2014 10:15 AM

Galectin Therapeutics, Inc. Presents at FSXinterlinked Investment Conference, Aug-01-2014 10:15 AM. Venue: Four Seasons Westlake Village, California, United States. Speakers: James Czirr, Executive Chairman of the Board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALTU:US $13.64 USD 0.00

GALTU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GALTU.
View Industry Companies
 

Industry Analysis

GALTU

Industry Average

Valuation GALTU Industry Range
No financial data is available for GALTU.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALECTIN THERAPEUTICS - UTS, please visit www.galectintherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.